257 related articles for article (PubMed ID: 16014753)
21. 2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.
Meltzer PC; Liang AY; Madras BK
J Med Chem; 1996 Jan; 39(2):371-9. PubMed ID: 8558504
[TBL] [Abstract][Full Text] [Related]
22. The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization.
Velázquez-Sánchez C; Ferragud A; Murga J; Cardá M; Canales JJ
Eur Neuropsychopharmacol; 2010 Jul; 20(7):501-8. PubMed ID: 20413276
[TBL] [Abstract][Full Text] [Related]
23. Effects of benztropine on behavioral and toxic effects of cocaine: comparison with atropine and the selective dopamine uptake inhibitor 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine.
Acri JB; Siedleck BK; Witkin JM
J Pharmacol Exp Ther; 1996 Apr; 277(1):198-206. PubMed ID: 8613919
[TBL] [Abstract][Full Text] [Related]
24. Locomotor activity induced by noncompetitive NMDA receptor antagonists versus dopamine transporter inhibitors: opposite strain differences in inbred long-sleep and short-sleep mice.
Hanania T; Zahniser NR
Alcohol Clin Exp Res; 2002 Apr; 26(4):431-40. PubMed ID: 11981117
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic-like properties of a dopamine uptake inhibitor in animal models of amphetamine addiction.
Velazquez-Sanchez C; Ferragud A; Renau-Piqueras J; Canales JJ
Int J Neuropsychopharmacol; 2011 Jun; 14(5):655-65. PubMed ID: 20735880
[TBL] [Abstract][Full Text] [Related]
26. σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration.
Hiranita T; Hong WC; Kopajtic T; Katz JL
J Pharmacol Exp Ther; 2017 Jul; 362(1):2-13. PubMed ID: 28442581
[TBL] [Abstract][Full Text] [Related]
27. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans.
Villemagne VL; Rothman RB; Yokoi F; Rice KC; Matecka D; Dannals RF; Wong DF
Synapse; 1999 Apr; 32(1):44-50. PubMed ID: 10188637
[TBL] [Abstract][Full Text] [Related]
28. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat.
Baumann MH; Char GU; De Costa BR; Rice KC; Rothman RB
J Pharmacol Exp Ther; 1994 Dec; 271(3):1216-22. PubMed ID: 7996429
[TBL] [Abstract][Full Text] [Related]
29. Behavioral effects of novel cocaine analogs: a comparison with in vivo receptor binding potency.
Cline EJ; Scheffel U; Boja JW; Carroll FI; Katz JL; Kuhar MJ
J Pharmacol Exp Ther; 1992 Mar; 260(3):1174-9. PubMed ID: 1545384
[TBL] [Abstract][Full Text] [Related]
30. Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys.
Woolverton WL; Hecht GS; Agoston GE; Katz JL; Newman AH
Psychopharmacology (Berl); 2001 Apr; 154(4):375-82. PubMed ID: 11349390
[TBL] [Abstract][Full Text] [Related]
31. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors.
Loland CJ; Desai RI; Zou MF; Cao J; Grundt P; Gerstbrein K; Sitte HH; Newman AH; Katz JL; Gether U
Mol Pharmacol; 2008 Mar; 73(3):813-23. PubMed ID: 17978168
[TBL] [Abstract][Full Text] [Related]
32. Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis.
Raje S; Cornish J; Newman AH; Cao J; Katz JL; Eddington ND
Biopharm Drug Dispos; 2006 Jul; 27(5):229-40. PubMed ID: 16586462
[TBL] [Abstract][Full Text] [Related]
33. Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter.
Zhao G; Li S; Qin GW; Fei J; Guo LH
J Ethnopharmacol; 2007 Jul; 112(3):498-506. PubMed ID: 17555897
[TBL] [Abstract][Full Text] [Related]
34. Novel tropane-based irreversible ligands for the dopamine transporter.
Zou MF; Kopajtic T; Katz JL; Wirtz S; Justice JB; Newman AH
J Med Chem; 2001 Dec; 44(25):4453-61. PubMed ID: 11728190
[TBL] [Abstract][Full Text] [Related]
35. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).
Matecka D; Rothman RB; Radesca L; de Costa BR; Dersch CM; Partilla JS; Pert A; Glowa JR; Wojnicki FH; Rice KC
J Med Chem; 1996 Nov; 39(24):4704-16. PubMed ID: 8941383
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation.
Kulkarni SS; Grundt P; Kopajtic T; Katz JL; Newman AH
J Med Chem; 2004 Jun; 47(13):3388-98. PubMed ID: 15189035
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling.
Raje S; Cornish J; Newman AH; Cao J; Katz JL; Eddington ND
Pharm Res; 2005 Apr; 22(4):603-12. PubMed ID: 15846468
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse.
Syed SA; Newman AH; Othman AA; Eddington ND
J Pharm Sci; 2008 May; 97(5):1993-2007. PubMed ID: 17879975
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship studies of novel 4-[2-[bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: synthesis and biological evaluation at the dopamine and serotonin transporter sites.
Dutta AK; Xu C; Reith ME
J Med Chem; 1996 Feb; 39(3):749-56. PubMed ID: 8576918
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation.
Gorentla BK; Vaughan RA
Neuropharmacology; 2005 Nov; 49(6):759-68. PubMed ID: 16181646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
